New vaccine support (NVS) for PNEUMO

GAVI’s support for new vaccines presents an opportunity for countries to not only implement vaccines that protect against diseases causing substantial morbidity and/or mortality, but also to build upon the vaccine investments in order to increase immunisation coverage rates, and strengthen routine immunisation services and primary health care systems. Pneumococcal vaccines can protect children from Streptococcus pneumoniae, which is the most common cause of severe pneumonia among children living in the developing world, and can also causes meningitis and sepsis. In line with WHO recommendations, GAVI support for pneumococcal vaccines is for routine infant immunisation. Two pneumococcal conjugate vaccines are currently available with GAVI support: a 10-valent (PCV10) and a 13-valent (PCV13).

ID Projet
47122-1820-LBR-12D-X
Statut de l'activité
2 - Implementation
Type d'aide
B02 - Contributions aux budgets réguliers des institutions multilatérales
% to Libéria
100.00

Organisations

Funding
The Global Alliance for Vaccination and Immunisation
Extending
World Health Organisation - core voluntary contributions account (for technical assitance)
Accountable
Federal States & Local Governments
Implementing
Federal States & Local Governments
Extending
United Nations Childrens Fund

Versements par exercice fiscal, trimestre

Exercice fiscal Trimestre fiscal Montant (USD) Libéria Montant (USD)
2018 Q2 890,118.00 890,118.00
2018 Q1 -26,460.00 -26,460.00
2017 Q4 796,980.00 796,980.00
2017 Q2 824,030.00 824,030.00

Engagements par exercice fiscal, trimestre

Exercice fiscal Trimestre fiscal Montant (USD) Libéria Montant (USD)
2018 Q2 1,435,000.00 1,435,000.00
2017 Q2 1,777,000.00 1,777,000.00

Projections de CDMT par exercice fiscal

Exercice fiscal Montant (USD) Libéria Montant (USD)
2020 995,250.00 995,250.00
2019 1,916,500.00 1,916,500.00
2018 1,809,750.00 1,809,750.00
2017 888,500.00 888,500.00

Code CRS %
Lutte contre les maladies infectieuses (12250) 100.0